Friday, December 15, 2017 2:50:10 PM
RMAT allows the FDA to approve with a range of support from fast track - commercialization generally within 6 months, to rolling approvals, and priority review, to finally BLA - allowing the company to market their product immediately and update the FDA with the results of the procedures as they come in (now also known as phase 4). Allowing USRM to market their heart procedure immediately would be the best of all worlds, but even fast track would save the company $10's of millions in further testing.
Myocell was in phase 2/3 when they stopped the trials due to financial constraints. They reopened those trials with the RMAT app, but they have not done anything officially with the trials since reopening. Any work they do outside the country or in RTT states can be used to support RMAT approval.
If USRM were to get fast track, they would likely be acquired by a BP. If they were to get phase 4 approval, they could have their choice of being acquired or they could go it alone as a major player.
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM